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Steroids That Induce Lung Maturation
Acutely Affect Higher Cortical Function:
A Fetal Magnetoencephalography Study
Uwe Schneider, MD1, Christian Arnscheidt, MD1,
Matthias Schwab, MD2, Jens Haueisen, PhD3,4,
Hans Joachim Seewald, MD1, and Ekkehard Schleussner, MD1
Abstract
Objective: To investigate whether steroids that induce lung maturation have acute effects on higher cortical function in the
human fetus.Methods: Cortical auditory-evoked responses (CAERs) were recorded from 10 singleton fetuses between 29 and
34 gestational weeks by fetal magnetoencephalography (fMEG) using transabdominal auditory stimulation prior to and within
3 hours after administering 2  12 mg of betamethasone, at an interval of 18 and 24 hours. Results: The components of the
CAER complex were categorized according to their latency: P2pm (186 þ 20 ms, 90%), N2pm (260 þ 34 ms, 50%), P3pm
(474 þ 36, 50%). In almost all of these cases the peak latencies of the fetal P2pm (P ¼ .042) and P3pm (P ¼ .043) were delayed
after exposure to betamethasone (Wilcoxon rank test). The trend was also observable in N2pm (P ¼ .08). Conclusion: Admin-
istration of betamethasone to expectant mothers was associated with acute change in higher cortical functions in the exposed
fetuses. Implications regarding functional brain development need further evaluation.
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Introduction
Synthetic steroids have been used to accelerate premature lung
maturation in fetuses threatened with preterm delivery for more
than 30 years.1,2 The rate of preterm deliveries is approxi-
mately 11% to 14% in the United States and constitutes a major
health issue.3 Prenatal steroid exposure prior to the completion
of 34 weeks of gestation leads to a significant reduction in the
occurrence and severity of respiratory distress syndrome in
those preterm neonates, a decrease in the incidence and severity
of intracerebral hemorrhage, ventriculomalacia and periventri-
cular leucomalacia, and hence reduces neonatal morbidity and
mortality associated with extreme and early preterm delivery.4-9
The prediction of imminent preterm delivery remains diffi-
cult. Depending on the methods of triage, a considerable num-
ber of women and fetuses have to be considered overtreated
and do not profit from steroid exposure.10
The in utero exposure to synthetic steroids has been shown
to trigger undesired effects in common monitoring parameters
of the fetus such as heart rate patterns, heart rate variation, and
gross body movements.11-14 These changes may be due to ster-
oid effects on the brain stem. They could be observed from
about 24 hours after injection and were of transient character.
Interestingly, the behavioral effects were more pronounced in
fetuses between 29 and 34 weeks than those earlier in
gestation.13
Relevant to these observations in human fetuses, there have
been a variety of reports from experimental studies using dif-
ferent animal models, which suggest that there might be both
transient and even permanent effects of intrauterine steroid
exposure onto functional forebrain development.15-22 Schwab
et al have shown decreased complexity in the spontaneous elec-
troencephalograph (EEG) activity in instrumented fetal sheep
within 24 hours after betamethasone administration.22 These
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changes in EEG activity were accompanied by transient altera-
tions in the neuronal cytoskeleton and synaptophysin, a synap-
tic marker protein,23 and a decrease in cerebral blood flow by
about 40%.24
Fetal magnetoencephalography (fMEG) is a noninvasive
method to examine human fetal brain function.23-28 It has in the
past delivered best results when using auditory stimuli to ana-
lyze the long latency cortical auditory-evoked response
(CAER) complex. It has been shown that the viability of this
method begins from about 28 weeks of gestation.27,28 The
CAERs reflect cerebral information processing rather than
spread of excitation.29,30 The sound pressure levels in the fre-
quency range used in these studies (500-1000 Hz) are attenu-
ated by 30 to 40 dB by traversing through the layers of the
abdominal and uterine walls, producing an intrauterine sound
of 60 dB, which can be considered safe for the developing audi-
tory organ.28
Although steroid effects on the biophysical profile of human
fetuses suggest changes in brain stem function and changes in
the EEG of fetal sheep are indicative of effects on higher brain
function, it is unclear whether antenatal steroid administration
affects cortical function in human fetuses. We hypothesize that
fMEG as a window to directly observe cortical processing in
the human fetus will reveal steroidal effects on higher brain
function during the time span when brain stem effects have
been reported.
Methods
Participants
The study design was approved by the ethics commission of the
Medical Faculty of the Friedrich Schiller University Jena. All
participants were inpatients of the Department of Obstetrics
at the University Hospital of the Friedrich Schiller University
Jena, Germany. The participants were consecutively selected
from the inpatient collective, according to the inclusion and
exclusion criteria stated below. All participants chose to partic-
ipate after the study protocol had been discussed and written
informed consent was obtained. The patients were under con-
tinuous medical observation.
The patients received a course of 2  12 mg of betametha-
sone at an interval of 18 to 24 hours to accelerate fetal lung
maturation on medical grounds (shortened cervical length of
<30 mm + premature uterine contractions). Administration
was strictly independent of participation in the study. In all but
1 case (patient # 4), the recordings were taken between 2 and
4 PM. The administration of the first dose immediately followed
the return of the patients to the unit, and the second injection
was timed between 11 and 12 AM the next day. In no case did
the time between the second injection and the study recording
exceeded 3 hours.
Inclusion criteria were maternal well-being, age >18 years,
antenatal steroid administration for medical reasons, and writ-
ten informed consent. To be studied, the women had to be
transferred from the Department of Obstetrics to the
biomagnetic facility. Therefore, high-risk conditions such as
premature rupture of the membranes, progressive dilatation
of the cervix, or persistent rhythmic uterine contractions during
the time of triage led to exclusion from the study. In addition,
sonographic signs of cerebral abnormalities, intrauterine
growth restriction, preeclampsia, multiplets, and preexisting
chronic maternal disease were defined as exclusion criteria.
Data Acquisition and Analysis
All measurements were performed in the magnetically shielded
room (AK 3b, Vakuumschmelze Hanau) of the Biomagnetic
Center Jena with a 31-channel superconducting quantum inter-
ference device (SQUID) biomagnetometer (Philips, Hamburg,
Germany; Figure 1). The recordings are an entirely safe and
passive procedure. The only energy delivered to the fetus is
auditory stimuli of physiological intensity (sound pressure
level comparable to maternal voice in utero).28
The experimental setting, data acquisition, and processing
are described extensively by Schneider et al 2001.26 In brief,
each participant participated in 2 recording sessions of similar
design: one prior to the first betamethasone administration, and
a second within 3 hours after the second administration. Ultra-
sound was used to determine fetal position, to localize the fetal
head, and to position the biomagnetometer (Figure 1). Each
session consisted of 2 separate continuously recorded segments
of 250 seconds (sampling rate 1000 Hz, band-pass filters 0.3 to
500 Hz). During these 2 segments, auditory stimuli of 500 Hz
Figure 1. Experimental setting inside the magnetically shielded room
with the sound applicator and Dewar in position. The recording
system consists of 31 helium-cooled superconducting quantum
interference devices (SQUIDs) fed by the corresponding number of
symmetrical first-order gradiometers (coil diameter of 20 mm;
baseline of 70 mm) arranged in an array of 145 mm in diameter. The
system noise is below 10 fT Hz 1/2 above 1 Hz.
100 Reproductive Sciences 18(1)
 at Technische Universität Ilmenau on October 14, 2014rsx.sagepub.comDownloaded from 
Figure 2. Examples of fetal cortical auditory evoked responses (CAERs). A, P2pm and N2pm components in 2 channels from the same
recording with inverse polarity. B, Single channel plot of P2pm prior to (upper trace) and 3 hours after (lower trace) the second injection of
betamethasone (patient 6 peak latencies P2pm 150 vs 172 ms). Note: no further components are in the same channels specifically for this fetus.
Note: P for surface positive waves and N for surface negative waves (Rotteveel et al.)
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tone frequency, 50 ms duration, a sound pressure level of 100
dB in air, and a variable interstimulus interval between 0.8 and
1.2 seconds were applied. The recordings were performed after
an initial segment of quiescence and separated by another seg-
ment of quiescence of 250 seconds each. The auditory stimuli
were delivered to the maternal abdomen from outside the mag-
netically shielded room via a 5-m plastic tube.
Data were preprocessed to remove (a) maternal and fetal
cardiomagnetic activity and (b) random noise. (a) Maternal
and, consecutively, fetal QRS complexes were averaged by
performing template-based maximum coherence matching and
these averages were subtracted from the raw data.28,31 This
fetal beat-to-beat interval data were used to assess the ongoing
level of fetal activity (see next paragraph) (b) The preprocessed
data underwent triggered averaging after band-pass filtering
and offset correction.28
Signal verification was based on waveform comparison
between the independent segments 1 and 2 of each session. If
identical waveforms and peak latencies could be obtained from
separate averaging of both segments, grand averages were cal-
culated for latency determination.32,33
As described previously, the components of the CAER
complex were categorized according to their latency following
the classification proposed in preterm neonates by Rotteveel
et al.34 In accordance to these findings, we designated the
early components P1pm-N1pm and the late components
P2pm-N2pm-P3pm (p for premature, m for magnetic; Fig-
ure 2).25,27,28 Following scientific convention, Rotteveel et al.
used P for surface positive waves and N for surface negative
waves in their EEG study performed in prematurely born
infants.32,34
Visual Assessment of Fetal Activity
During data processing, the time instants of the fetal QRS
complexes are determined to achieve cardiac interference
reduction. This information was used to calculate and, retro-
spectively, display the fetal heart rate pattern (fHRP) during the
recordings.35 The fHRPs were classified by an obstetrician
with routine experience in nonstress test assessment. Classifi-
cation was based on specific visual criteria. Fetal quiescence
was defined by a stable heart rate (variation of floating baseline
of <10 bpm/3 min); oscillation bandwidth < + 5 bpm; only
isolated accelerations of >15 bpm/>15 seconds, and a floating
baseline heart rate <160 bpm. These fHRPs were designated
fHRP I. All fHRPs that did not fulfill these criteria were
denominated fHRP II.36
Results
A total of 10 participants underwent 20 successful sessions,
allowing intraindividual comparison of component latencies.
Table 1 summarizes the clinical characteristics. Of the initially
recruited 12 women pregnant with singletons, the data of 2 had
to be retrospectively excluded from analysis due to technical
problems during the recording (patients # 2 and 4, see Table 1).
Dosages of concurrent medication did not change between the
consecutive sessions. One fetus was known to have a gastro-
schisis (patient # 9). In 3 cases the mode of delivery was
cesarean section. In all, 5 of the infants were female and 7 were
male (Table 1). Within a single session, the fetal position did
not change in any case. Ultrasound examination showed that
maximum depth of the fetal head was 4.7 cm.
In each of the 20 separate sessions, at least 1 component
of the fetal CAER could be detected. For the intraindividual
comparison of latency before and after betamethasone
administration, only those signals were used in which a
component could be detected in both consecutive sessions.
Five different components could be distinguished (mean
latency þ SD, percentage of detection): P1pm 76 þ 9 ms,
20%; N1pm 109 þ 9 ms, 20%; P2pm 186 þ 20 ms, 90%;
N2pm 260 þ 34 ms, 50%; P3pm 474 þ 36, 50%. Absolute
Table 1. Pregnancy-Related and Perinatal Outcome Dataa
Patient Number Age (years) G/P Tocolysis GA (weeks) EFW (g) GAD (weeks) BW (g) Gender (M/F) APGAR 5
1 27 1/0 Fenoterol 32 1925 35 2400 F 7
2* 28 1/0 Fenoterol 31 2033 39 2885 M 9
3 31 4/2 – 31 1830 40 4040 M 10
4* 21 1/0 – 34 2548 37 2510 F 9
5 30 2/0 Fenoterol 33 2236 39 3390 F 9
6 18 1/0 Fenoterol 32 1930 35 2949 M 9
7 36 2/1 NO 31 1860 39 3330 M 9
8 26 1/0 NO 29 1630 37 2990 F 10
9 20 1/0 – 30 1485 34 2180 M 9
10 29 1/0 - 31 2160 36 2550 M 8
11 23 1/0 – 31 1612 37 2630 M 9
12 31 1/0 – 30 1950 36 2630 F 9
Abbreviations: G/P, gravida/para, number of pregnancies including the current/number of previous deliveries; GA, gestational age at the time of investigation; EFW,
estimated fetal weight; GAD, gestational age at the time of delivery; BW, birth weight; gender, gender of the newborn; APGAR 5, APGAR assessment at 5 minutes;
NO, transdermal application of nitroglycerin.
a Patients are consecutively numbered. Weeks of gestation are given as completed weeks. Patients 2 and 4 who had to be retrospectively excluded from the study
indicated with an asterisk symbol.
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numbers of individual peak latencies of the fetuses are dis-
played in Figure 3A-C.
In a significant number of cases the occurrence of the fetal
P2pm and P3pm components were delayed after exposure to
betamethasone when compared to the control conditions
(P2pm P ¼ .042, median 178 vs 187 ms; P3pm P ¼ .043, med-
ian 466 vs 484 ms; Wilcoxon rank test). The trend was also
observable in the N2pm component not reaching the appropri-
ate level of statistical significance (P ¼ .08, median 269 vs 280
ms; Wilcoxon rank test).
The margin of latency delay from 180 þ 16 ms to 192 þ 23
ms (mean þ SD) was statistically significant for the P2pm
component (P ¼ .027; paired student t test). Normal distribu-
tion was confirmed by Shapiro-Wilk testing. In contrast, owing
to the small number of cases (only 5 cases each), the N2pm
(from 257 þ 34 to 278 þ 28 ms, mean þ SD, P ¼ .073) and
P3pm (from 464þ 17 to 498þ 41, meanþ SD, P¼ .104) com-
ponents displayed a trend to delayed mean latencies after
intrauterine betamethasone exposure.
When testing for possible confounders, we observed that the
effect on P2pm was correlated with gestational age (Figure 4).
Although P2pm in the control condition did not change signif-
icantly with age (r2¼.36; P¼ .41, Spearman), both the peak
latencies after betamethasone exposure (r2 ¼ .61; P ¼ .083,
Spearman) and the absolute intraindividual differences in peak
latency (r2 ¼ .60; P ¼ .068, Spearman) displayed a trend
toward a negative correlation with increasing gestational age
(Figure 4). The 3 fetuses in the advanced gestational age were,
in addition, exposed to fenoterol (Table 1). When excluding
these fetuses post hoc from correlation analysis, the above
described correlation factors became statistically significant
(control condition, study condition, absolute difference
P2pm: all r2 ¼ .83; P ¼ .039, Spearman).
Of the 10 fetuses, 7 presented with a fHRP II during both
recording conditions. In 2 cases (case #s 7 and 9), the fetuses dis-
played fHRP II during control and fHRP I during the post expo-
sition conditions. The fHRP of the remaining fetus (case 1)
fulfilled the visual criteria of fetal quiescence during both
recordings. In those rare cases where gestational ages and con-
current medications were comparable, the fHRP did not relate
to any obvious systematic differences in the latencies of P2pm
(ie, cases 1 vs 5; 9 vs 8 or 12; 7 vs 11; see Table 1 and Figure 3A).
Discussion
We examined the acute effects of betamethasone on the long
latency components of the CAERs as markers for cerebral sti-
mulus processing. After the intrauterine exposure to betametha-
sone at the dose used to accelerate fetal lung maturation, we
observed a delayed cortical processing of the pure 500-Hz tone
used as a stimulus here in almost all of the cases studied. To our
knowledge, this is the first study demonstrating acute effects of
antenatal steroid administration on higher brain function of the
human fetus. The data are in agreement with the suspicion of
acute steroid effects on cortical brain function, which has
emerged from experimental studies.22
Figure 3. Individual peak latencies of the cortical auditory evoked
response (CAER) components. Comparison of the peak latencies of
(A) P2pm, (B) N2pm, and (C) P3pm between control (prior to
betamethasone administration) and betamethasone (after betametha-
sone administration) conditions. Case number refers to those given in
Table 1. The data from patients # 2 and 4 had to be excluded from
further analysis due to technical defects of the recordings.
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The previous studies examining the effects of prenatal
steroid therapy onto evoked cerebral activity were performed
after delivery and hence at variable times following betametha-
sone administration.36-38 de Zegher et al described a transient
acceleration of the N1 component in somatosensory evoked
potentials within the first week of life when betamethasone was
combined with thyrotropin to induce prenatal acceleration of
lung maturation.36 In contrast to the current study the described
effect most likely represents a maturational influence rather
than an acute effect on fetal brain function. In 2 other studies
neither the short latency auditory brain stem response nor the
visually evoked cortical response were affected in premature
newborns by antenatal steroid exposure.36,39 Amplitudes of
CAER were shown to be influenced by steroid application in
adults.39,40 They are generally small in fMEG and cannot be
considered a dependent parameter because of the varying dis-
tance between sensors and source but may have an impact on
overall detection.28
That the cortical function of premature fetuses is primarily
affected is in agreement with the data from Colberg et al, show-
ing a more pronounced decrease in synaptic density to beta-
methasone exposure in fetal sheep at 0.7 gestation compared
to fetal sheep at 0.83 gestation.41
Two types of steroid receptors have been described in the
brain: mineralocorticoid or type I receptors are almost
exclusively distributed in the hippocampus. They show
excitatory effects mediated by suppressing serotonergic hyper-
polarization, leading to perpetuation of synaptic transmission.
Glucocorticoid or type II receptors, which occur throughout the
brain, tend to decrease neuronal excitability via interaction
with the noradrenergic system.42-45 Synthetic steroids as such
bind almost exclusively to type II receptors.44,46
There are several possible confounders to our observations:
All the recordings were performed in the early afternoon to
control for diurnal changes, but we did not control for diet, bev-
erage consumption, or other habits the participants might have
had. The cerebral processing of auditory stimuli relates to the
sleep state of the participant.46 Acute cortisol administration
is known to promote nonrapid eye movement (REM) sleep
in human beings.47 The peak latency of the CAER is known
to increase during quiet sleep.30 The pre-classification of fetal
activity levels from a visual inspection of fHRP is not the
current multimodal state-of-the-art method to assign the fetal
behavioral state.48 Ultrasound observation during fMCG
recordings is not readily applicable because of its magnetic
interference on the signal. With only minimal means to com-
pare fetal activity level, such effects were not observed.
In our sample of 12women, only 1 eventually delivered prior
to the completion of 34 weeks of gestation, whereas 8 gave
birth prematurely. These outcome parameters underline the
Figure 4. Latency relation with gestational age. Controls—P2pm peak latency prior to betamethasone exposure (r2 ¼ .36; P ¼ .41); study
condition—P2pm peak latency after betamethasone exposure (r2 ¼ .61; P ¼ .089); latency difference—absolute intraindividual latency
differences of P2pm (r2 ¼ .60; P ¼ .068). All correlations were calculated using Spearman correlation coefficient.
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selection bias that had to be made according to the necessity of
transportation off the limits of the obstetric unit. More recently
the guidelines in our department were changed to a stricter
handling of antenatal steroid administration to reduce the
number of overtreated fetuses. Some of the participants in the
described sample would under current policies not have been
liable to receive steroid treatment. However, this stable sample
represents patientswith less choriodecidual inflammation, elim-
inating one of the potentially confounding factors. A confound-
ing effect of the concurrent tocolytic medication with fenoterol
cannot be ruled out.49 The major limitation to our study is the
small sample size that for the sake of controllable experimental
conditions in these participants restricts the statistical power to
nonparametrical testing and a narrow margin of statistical con-
viction. The fact that we observed a significant difference based
on P2pm only may be just related to the fact that we were able to
detect P2pm 90% of the time as opposed to other components
which varied between 20% and 50%.
Antenatal steroid administration has been a life saving mea-
sure for thousands of preterm neonates worldwide since its
introduction over 30 years ago. Long-term follow-up studies
have not shown persistent negative effects, therefore, the ben-
efits of treatment to date outweighs the potential risk.2,4
However, this study indicated that betamethasnoe adminis-
tration to the mother is associated with acute changes in higher
cortical function in the exposed fetuses. The results suggest that
a correlation might exist between the demonstrated effects and
the gestational age at the time of the exposure. This study
shows that it is mandatory for further in-depth investigation
to determine whether there are such associations and whether
these effects are transitory or permanent.
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